Opportunity for intervention to achieve American Heart Association guidelines for optimal lipid levels in high-risk women in a managed care setting
The American Heart Association (AHA) recently established evidence-based recommendations for cardiovascular disease (CVD) prevention in women, including lipid management. This study evaluated optimal lipid-level attainment and treatment patterns on the basis of these guidelines in high-risk women in...
Saved in:
Published in | Circulation (New York, N.Y.) Vol. 111; no. 4; pp. 488 - 493 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hagerstown, MD
Lippincott Williams & Wilkins
01.02.2005
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The American Heart Association (AHA) recently established evidence-based recommendations for cardiovascular disease (CVD) prevention in women, including lipid management. This study evaluated optimal lipid-level attainment and treatment patterns on the basis of these guidelines in high-risk women in a managed care setting.
We conducted a historical prospective cohort analysis of a 1.1-million-member, integrated, managed-care database. Eligible high-risk women were those with evidence of previous CVD or risk equivalent who had a full lipid panel available between October 1, 1999, and September 30, 2000; were naive to lipid therapy; and had a minimum of 12 months health plan eligibility preindex and postindex lipid panel. Optimal lipid levels were defined as LDL cholesterol (LDL-C) <100 mg/dL, HDL cholesterol (HDL-C) >50 mg/dL, non-HDL-C <130 mg/dL, and triglycerides <150 mg/dL. Laboratory values and lipid pharmacotherapy were assessed longitudinally over the postindex follow-up (up to 36 months). A total of 8353 high-risk women (mean age, 66+/-14 years) with a mean follow-up of 27+/-8 months were included. Only 7% attained optimal combined lipid levels initially, and this increased to 12% after 36 months. Lipid-modifying therapy was initiated in 32% of patients, including 35% of women with LDL-C > or =100 mg/dL and 15% with LDL-C <100 mg/dL.
Among high-risk women, few attained the AHA's standards for all lipid fractions, and only one third received recommended drug therapy, highlighting significant opportunities to apply evidence-based recommendations to manage lipid abnormalities in high-risk women. |
---|---|
AbstractList | The American Heart Association (AHA) recently established evidence-based recommendations for cardiovascular disease (CVD) prevention in women, including lipid management. This study evaluated optimal lipid-level attainment and treatment patterns on the basis of these guidelines in high-risk women in a managed care setting.
We conducted a historical prospective cohort analysis of a 1.1-million-member, integrated, managed-care database. Eligible high-risk women were those with evidence of previous CVD or risk equivalent who had a full lipid panel available between October 1, 1999, and September 30, 2000; were naive to lipid therapy; and had a minimum of 12 months health plan eligibility preindex and postindex lipid panel. Optimal lipid levels were defined as LDL cholesterol (LDL-C) <100 mg/dL, HDL cholesterol (HDL-C) >50 mg/dL, non-HDL-C <130 mg/dL, and triglycerides <150 mg/dL. Laboratory values and lipid pharmacotherapy were assessed longitudinally over the postindex follow-up (up to 36 months). A total of 8353 high-risk women (mean age, 66+/-14 years) with a mean follow-up of 27+/-8 months were included. Only 7% attained optimal combined lipid levels initially, and this increased to 12% after 36 months. Lipid-modifying therapy was initiated in 32% of patients, including 35% of women with LDL-C > or =100 mg/dL and 15% with LDL-C <100 mg/dL.
Among high-risk women, few attained the AHA's standards for all lipid fractions, and only one third received recommended drug therapy, highlighting significant opportunities to apply evidence-based recommendations to manage lipid abnormalities in high-risk women. BACKGROUNDThe American Heart Association (AHA) recently established evidence-based recommendations for cardiovascular disease (CVD) prevention in women, including lipid management. This study evaluated optimal lipid-level attainment and treatment patterns on the basis of these guidelines in high-risk women in a managed care setting.METHODS AND RESULTSWe conducted a historical prospective cohort analysis of a 1.1-million-member, integrated, managed-care database. Eligible high-risk women were those with evidence of previous CVD or risk equivalent who had a full lipid panel available between October 1, 1999, and September 30, 2000; were naive to lipid therapy; and had a minimum of 12 months health plan eligibility preindex and postindex lipid panel. Optimal lipid levels were defined as LDL cholesterol (LDL-C) <100 mg/dL, HDL cholesterol (HDL-C) >50 mg/dL, non-HDL-C <130 mg/dL, and triglycerides <150 mg/dL. Laboratory values and lipid pharmacotherapy were assessed longitudinally over the postindex follow-up (up to 36 months). A total of 8353 high-risk women (mean age, 66+/-14 years) with a mean follow-up of 27+/-8 months were included. Only 7% attained optimal combined lipid levels initially, and this increased to 12% after 36 months. Lipid-modifying therapy was initiated in 32% of patients, including 35% of women with LDL-C > or =100 mg/dL and 15% with LDL-C <100 mg/dL.CONCLUSIONSAmong high-risk women, few attained the AHA's standards for all lipid fractions, and only one third received recommended drug therapy, highlighting significant opportunities to apply evidence-based recommendations to manage lipid abnormalities in high-risk women. Background— The American Heart Association (AHA) recently established evidence-based recommendations for cardiovascular disease (CVD) prevention in women, including lipid management. This study evaluated optimal lipid-level attainment and treatment patterns on the basis of these guidelines in high-risk women in a managed care setting. Methods and Results— We conducted a historical prospective cohort analysis of a 1.1-million-member, integrated, managed-care database. Eligible high-risk women were those with evidence of previous CVD or risk equivalent who had a full lipid panel available between October 1, 1999, and September 30, 2000; were naive to lipid therapy; and had a minimum of 12 months health plan eligibility preindex and postindex lipid panel. Optimal lipid levels were defined as LDL cholesterol (LDL-C) <100 mg/dL, HDL cholesterol (HDL-C) >50 mg/dL, non–HDL-C <130 mg/dL, and triglycerides <150 mg/dL. Laboratory values and lipid pharmacotherapy were assessed longitudinally over the postindex follow-up (up to 36 months). A total of 8353 high-risk women (mean age, 66±14 years) with a mean follow-up of 27±8 months were included. Only 7% attained optimal combined lipid levels initially, and this increased to 12% after 36 months. Lipid-modifying therapy was initiated in 32% of patients, including 35% of women with LDL-C ≥100 mg/dL and 15% with LDL-C <100 mg/dL. Conclusions— Among high-risk women, few attained the AHA’s standards for all lipid fractions, and only one third received recommended drug therapy, highlighting significant opportunities to apply evidence-based recommendations to manage lipid abnormalities in high-risk women. |
Author | STANEK, Eric J WILLEY, Vincent J SARAWATE, Chaitanya BLUMENTHAL, Roger S MERZ, Noel Bairey WATSON, Karol E CZIRAKY, Mark J FABUNMI, Rosalind P MOSCA, Lori |
Author_xml | – sequence: 1 givenname: Lori surname: MOSCA fullname: MOSCA, Lori organization: Columbia University, New York, NY, United States – sequence: 2 givenname: Noel Bairey surname: MERZ fullname: MERZ, Noel Bairey organization: Cedars-Sinai Medical Center, Los Angeles, Calif, United States – sequence: 3 givenname: Roger S surname: BLUMENTHAL fullname: BLUMENTHAL, Roger S organization: Johns Hopkins Medical Institute, Baltimore, Md, United States – sequence: 4 givenname: Mark J surname: CZIRAKY fullname: CZIRAKY, Mark J organization: HealthCore, Inc, Wilmington, Del, United States – sequence: 5 givenname: Rosalind P surname: FABUNMI fullname: FABUNMI, Rosalind P organization: American Heart Association, Dallas, Tex, United States – sequence: 6 givenname: Chaitanya surname: SARAWATE fullname: SARAWATE, Chaitanya organization: HealthCore, Inc, Wilmington, Del, United States – sequence: 7 givenname: Karol E surname: WATSON fullname: WATSON, Karol E organization: University of California, Los Angeles, Los Angeles, Calif, United States – sequence: 8 givenname: Vincent J surname: WILLEY fullname: WILLEY, Vincent J organization: HealthCore, Inc, Wilmington, Del, United States – sequence: 9 givenname: Eric J surname: STANEK fullname: STANEK, Eric J organization: Kos Pharmaceuticals, Inc, Weston, Fla, United States |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16603473$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/15687138$$D View this record in MEDLINE/PubMed |
BookMark | eNpFkV1rFDEUhoNU7Lb6FyQIejdjMvma8W5Z1BYKBdHrkMmc2Y3OJGOSaenv8A-bbhc2N4eE533D4blCFz54QOgDJTWlkn4mtN7d_qhJOVSwVnS1lKSVdSteoQ0VDa-4YN0F2hSgqxRrmkt0ldLvcpVMiTfokgrZKsraDfp3vywh5tW7_ITHELHzGeID-OyCxzlgYw8OHgBvZ4jOGo9vwMSMtykF68yR2q9ugMl5SMeGsGQ3mwlPbnEDnkp4SqUWH9z-UEWX_uDHMIN_fjJ4Nt7sYcDWRMAJcnZ-_xa9Hs2U4N1pXqNf377-3N1Ud_ffb3fbu8pyTnKl2oaTFghTyohRcdK1vSpDCNaU5eQoeNcNY8NF0zOhbNOMgoxmMBK4FX3PrtGnl94lhr8rpKxnlyxMk_EQ1qSlYh1jjBfwywtoY0gpwqiXWFaMT5oS_axEE6qLEn1Woo9KdCtK-P3pl7WfYThHTw4K8PEEmGTNNEbjrUtnrjQxrhj7D7zVmHo |
CODEN | CIRCAZ |
CitedBy_id | crossref_primary_10_1016_j_clinthera_2007_01_004 crossref_primary_10_1016_j_anr_2012_05_002 crossref_primary_10_1016_j_ahj_2008_05_020 crossref_primary_10_1016_S0828_282X_10_70454_2 crossref_primary_10_1016_j_amjcard_2007_06_058 crossref_primary_10_2217_17460875_1_4_375 crossref_primary_10_1016_j_jacl_2012_06_006 crossref_primary_10_1016_j_recesp_2010_10_030 crossref_primary_10_1186_1476_511X_11_59 crossref_primary_10_1185_030079906X89856 crossref_primary_10_1007_s11883_008_0053_8 crossref_primary_10_3810_pgm_2009_03_1977 crossref_primary_10_1016_j_ijge_2013_03_002 crossref_primary_10_1016_j_whi_2007_04_001 crossref_primary_10_1185_03007995_2012_750602 crossref_primary_10_1111_j_1742_1241_2011_02643_x crossref_primary_10_1016_j_clinthera_2006_04_012 crossref_primary_10_1097_HJR_0b013e328338978e crossref_primary_10_1016_j_amjmed_2005_11_015 crossref_primary_10_1007_s11789_013_0051_4 crossref_primary_10_1155_2012_861924 crossref_primary_10_1111_j_1525_1497_2005_40239_x crossref_primary_10_1111_j_1753_4887_2006_tb00230_x crossref_primary_10_2217_WHE_11_29 crossref_primary_10_1089_jwh_2015_5271 crossref_primary_10_1016_j_amjcard_2015_10_007 crossref_primary_10_1007_s12170_012_0253_1 crossref_primary_10_1007_s12170_007_0026_4 crossref_primary_10_1007_s00392_010_0177_z crossref_primary_10_1097_JCN_0b013e318283b9fb crossref_primary_10_1016_j_jacc_2007_02_020 crossref_primary_10_1007_s10557_019_06883_z crossref_primary_10_1016_S0828_282X_07_70875_9 crossref_primary_10_1097_00005082_200609000_00003 crossref_primary_10_1016_j_amjcard_2006_05_057 crossref_primary_10_1016_j_whi_2014_06_004 crossref_primary_10_1016_j_amjcard_2012_07_028 crossref_primary_10_1177_1741826710389369 crossref_primary_10_1586_14779072_4_4_461 crossref_primary_10_1016_j_jacl_2010_03_002 crossref_primary_10_1185_03007995_2013_813842 crossref_primary_10_1177_1074248413514481 crossref_primary_10_1097_00005082_200611001_00004 crossref_primary_10_1016_j_nrl_2016_06_013 crossref_primary_10_1038_ncpcardio0516 crossref_primary_10_1016_j_ahj_2009_11_031 crossref_primary_10_1016_j_jacl_2008_06_009 crossref_primary_10_1185_03007990802134755 crossref_primary_10_1089_jwh_2013_4591 crossref_primary_10_1007_BF03076368 crossref_primary_10_1016_j_cjca_2011_01_007 crossref_primary_10_1016_j_jacc_2015_08_860 crossref_primary_10_1002_clc_20861 crossref_primary_10_1016_j_amjcard_2005_12_011 crossref_primary_10_1016_j_ijcard_2007_06_009 crossref_primary_10_1016_j_amjcard_2010_11_006 crossref_primary_10_1016_j_cjca_2013_06_013 crossref_primary_10_1212_01_wnl_0000268491_89956_c2 crossref_primary_10_1089_jwh_2009_1406 crossref_primary_10_1016_j_ahj_2006_05_013 crossref_primary_10_1016_j_whi_2007_03_002 crossref_primary_10_2217_clp_10_35 crossref_primary_10_1016_j_whi_2007_03_004 crossref_primary_10_1007_s00508_009_1152_4 crossref_primary_10_1016_j_ahj_2009_08_009 crossref_primary_10_1016_j_nrleng_2016_06_008 crossref_primary_10_1016_j_rec_2010_10_030 crossref_primary_10_1097_00044067_200601000_00010 crossref_primary_10_1097_01_NUMA_0000333719_42615_d8 crossref_primary_10_1016_j_amjcard_2007_12_009 crossref_primary_10_3109_09513590_2013_819084 crossref_primary_10_1161_JAHA_121_024107 crossref_primary_10_1089_jwh_2006_15_1116 crossref_primary_10_1016_j_disamonth_2006_03_001 |
Cites_doi | 10.1001/archinte.158.11.1238 10.1161/01.cir.0000114834.85476.81 10.1002/0471722146 10.1056/NEJM199908123410707 10.1016/0895-4356(92)90133-8 10.1001/jama.1993.03500230097036 10.1016/S0002-9149(99)00117-4 10.1001/jama.1993.03500230084034 10.1001/archinte.160.4.459 10.1016/1047-2797(92)90051-Q 10.1016/S0002-9149(99)00043-0 10.1016/S0140-6736(02)09327-3 10.1161/circ.99.18.2480 10.18553/jmcp.2004.10.2.130 10.2307/1912934 10.1161/circ.98.9.851 10.1161/circ.106.25.3143 10.1161/01.cir.0000066320.27195.b4 10.1177/070674370204700111 10.1016/S0002-9149(98)00227-6 10.1001/jama.1997.03540400031027 |
ContentType | Journal Article |
Copyright | 2005 INIST-CNRS |
Copyright_xml | – notice: 2005 INIST-CNRS |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1161/01.CIR.0000153859.66086.85 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic CrossRef |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Anatomy & Physiology |
EISSN | 1524-4539 |
EndPage | 493 |
ExternalDocumentID | 10_1161_01_CIR_0000153859_66086_85 15687138 16603473 |
Genre | Research Support, Non-U.S. Gov't Multicenter Study Journal Article |
GroupedDBID | --- .-D .3C .55 .GJ .XZ .Z2 01R 08R 0R~ 0ZK 18M 1CY 1J1 29B 2FS 2WC 354 40H 41~ 4Q1 4Q2 4Q3 53G 5GY 5RE 5VS 6PF 71W 77Y 7O~ AAAXR AAEJM AAGIX AAHPQ AAJCS AAMOA AAMTA AAPBV AAQKA AARTV AASOK AASXQ AAUGY AAWTL AAXQO AAYOK ABASU ABBUW ABDIG ABOCM ABPMR ABPTK ABQRW ABXVJ ABZAD ACCJW ACDDN ACEWG ACGFO ACGFS ACILI ACOAL ACRKK ACRZS ACWDW ACWRI ACXNZ ADBBV ADCYY ADFPA ADGGA ADNKB AE3 AE6 AEBDS AEETU AENEX AFCHL AFDTB AFFNX AFUWQ AGINI AHMBA AHOMT AHRYX AHVBC AIJEX AJIOK AJJEV AJNWD AJNYG AKALU AKULP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW ASPBG AVWKF AWKKM AYCSE AZFZN BAWUL BOYCO BQLVK BS7 BYPQX C1A C45 CS3 DIK DIWNM DU5 DUNZO E.X E3Z EBS EEVPB EJD EX3 F2K F2L F2M F2N F5P FCALG FEDTE FL- FW0 GNXGY GQDEL GX1 H0~ H13 HZ~ H~9 IKREB IKYAY IN~ IPNFZ IQODW J5H JF9 JG8 JK3 JK8 K-A K-F K8S KD2 KMI KQ8 L-C L7B M18 MVM N4W N9A NEJ N~7 N~B N~M O9- OAG OAH OBH OCB OCUKA ODA ODMTH OGEVE OHH OHT OHYEH OJAPA OK1 OL1 OLB OLG OLH OLU OLV OLW OLY OLZ OPUJH ORVUJ OUVQU OVD OVDNE OVIDH OVLEI OVOZU OWBYB OWU OWV OWW OWX OWY OWZ OXXIT P-K P2P PQQKQ R58 RAH RHF RIG RLZ S4R S4S T8P TEORI TR2 TSPGW UPT V2I VVN W2D W3M W8F WH7 WHG WOQ WOW X3V X3W X7M XXN XYM YFH YOC YQJ YSK YXB YYM YYP YZZ ZA5 ZFV ZGI ZXP ZY1 ZZMQN ~H1 AAAAV AAIQE AAUEB ABJNI ADHPY AFEXH AHQNM AINUH AJZMW CGR CUY CVF ECM EIF NPM AASCR AAYXX ABVCZ ACXJB AFSOK CITATION ERAAH HLJTE HVGLF 7X8 |
ID | FETCH-LOGICAL-c440t-782408e0377a5f74098b774055327136f5499df2452b357c22f50fada6e4c5bb3 |
ISSN | 0009-7322 |
IngestDate | Fri Aug 16 01:38:50 EDT 2024 Fri Aug 23 01:12:49 EDT 2024 Tue Oct 15 23:29:09 EDT 2024 Sun Oct 22 16:06:18 EDT 2023 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Keywords | Human American Managed care Risk factor Lipids Cardiovascular disease Lipoprotein cardiovascular diseases Cholesterol lipoproteins women |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c440t-782408e0377a5f74098b774055327136f5499df2452b357c22f50fada6e4c5bb3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://doi.org/10.1161/01.cir.0000153859.66086.85 |
PMID | 15687138 |
PQID | 67393334 |
PQPubID | 23479 |
PageCount | 6 |
ParticipantIDs | proquest_miscellaneous_67393334 crossref_primary_10_1161_01_CIR_0000153859_66086_85 pubmed_primary_15687138 pascalfrancis_primary_16603473 |
PublicationCentury | 2000 |
PublicationDate | 2005-02-01 |
PublicationDateYYYYMMDD | 2005-02-01 |
PublicationDate_xml | – month: 02 year: 2005 text: 2005-02-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | Hagerstown, MD |
PublicationPlace_xml | – name: Hagerstown, MD – name: United States |
PublicationTitle | Circulation (New York, N.Y.) |
PublicationTitleAlternate | Circulation |
PublicationYear | 2005 |
Publisher | Lippincott Williams & Wilkins |
Publisher_xml | – name: Lippincott Williams & Wilkins |
References | e_1_3_2_9_2 e_1_3_2_15_2 e_1_3_2_8_2 e_1_3_2_16_2 e_1_3_2_7_2 e_1_3_2_17_2 e_1_3_2_6_2 e_1_3_2_18_2 e_1_3_2_19_2 e_1_3_2_1_2 e_1_3_2_10_2 e_1_3_2_21_2 e_1_3_2_5_2 e_1_3_2_11_2 e_1_3_2_22_2 e_1_3_2_4_2 e_1_3_2_12_2 e_1_3_2_23_2 e_1_3_2_3_2 e_1_3_2_13_2 e_1_3_2_2_2 e_1_3_2_14_2 (e_1_3_2_20_2) 1994; 344 |
References_xml | – ident: e_1_3_2_17_2 doi: 10.1001/archinte.158.11.1238 – ident: e_1_3_2_8_2 doi: 10.1161/01.cir.0000114834.85476.81 – ident: e_1_3_2_11_2 doi: 10.1002/0471722146 – volume: 344 start-page: 1383 year: 1994 ident: e_1_3_2_20_2 publication-title: Lancet – ident: e_1_3_2_21_2 doi: 10.1056/NEJM199908123410707 – ident: e_1_3_2_10_2 doi: 10.1016/0895-4356(92)90133-8 – ident: e_1_3_2_22_2 doi: 10.1001/jama.1993.03500230097036 – ident: e_1_3_2_1_2 – ident: e_1_3_2_15_2 doi: 10.1016/S0002-9149(99)00117-4 – ident: e_1_3_2_3_2 doi: 10.1001/jama.1993.03500230084034 – ident: e_1_3_2_14_2 doi: 10.1001/archinte.160.4.459 – ident: e_1_3_2_5_2 doi: 10.1016/1047-2797(92)90051-Q – ident: e_1_3_2_6_2 doi: 10.1016/S0002-9149(99)00043-0 – ident: e_1_3_2_7_2 doi: 10.1016/S0140-6736(02)09327-3 – ident: e_1_3_2_23_2 doi: 10.1161/circ.99.18.2480 – ident: e_1_3_2_19_2 doi: 10.18553/jmcp.2004.10.2.130 – ident: e_1_3_2_12_2 doi: 10.2307/1912934 – ident: e_1_3_2_16_2 doi: 10.1161/circ.98.9.851 – ident: e_1_3_2_4_2 doi: 10.1161/circ.106.25.3143 – ident: e_1_3_2_2_2 doi: 10.1161/01.cir.0000066320.27195.b4 – ident: e_1_3_2_9_2 doi: 10.1177/070674370204700111 – ident: e_1_3_2_13_2 doi: 10.1016/S0002-9149(98)00227-6 – ident: e_1_3_2_18_2 doi: 10.1001/jama.1997.03540400031027 |
SSID | ssj0006375 |
Score | 2.1758075 |
Snippet | The American Heart Association (AHA) recently established evidence-based recommendations for cardiovascular disease (CVD) prevention in women, including lipid... Background— The American Heart Association (AHA) recently established evidence-based recommendations for cardiovascular disease (CVD) prevention in women,... BACKGROUNDThe American Heart Association (AHA) recently established evidence-based recommendations for cardiovascular disease (CVD) prevention in women,... |
SourceID | proquest crossref pubmed pascalfrancis |
SourceType | Aggregation Database Index Database |
StartPage | 488 |
SubjectTerms | Adult Aged American Heart Association Biological and medical sciences Blood and lymphatic vessels Cardiology. Vascular system Cholesterol, HDL - blood Cholesterol, LDL - blood Cohort Studies Combined Modality Therapy Coronary heart disease Databases, Factual Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous Evidence-Based Medicine Female Follow-Up Studies Fundamental and applied biological sciences. Psychology General aspects Goals Heart Humans Hyperlipidemias - blood Hyperlipidemias - drug therapy Hyperlipidemias - epidemiology Hypolipidemic Agents - therapeutic use Lipids - blood Managed Care Programs Medical sciences Metabolic Syndrome - blood Metabolic Syndrome - drug therapy Metabolic Syndrome - epidemiology Middle Aged Patient Compliance Practice Guidelines as Topic Prospective Studies Risk Treatment Outcome Triglycerides - blood Vertebrates: cardiovascular system |
Title | Opportunity for intervention to achieve American Heart Association guidelines for optimal lipid levels in high-risk women in a managed care setting |
URI | https://www.ncbi.nlm.nih.gov/pubmed/15687138 https://search.proquest.com/docview/67393334 |
Volume | 111 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1di9NAFB3qCiKI6K4f9WOdB_GlpKaZmaR9XItaxSosu9C3MJNM1kCblDZd2P4Nf4v_zzt3Jk1Wt6C-hDJJJpBzenPvzLn3EvI6DYRijAsv05mAACUZeooNMk-kKg1louELZbKRp1_DyTn_PBOzTudnS7W0qVQ_2d6YV_I_qMIY4GqyZP8B2d2kMAC_AV84AsJw_CuMvy2N97wpcie7zNsCRnAqjVBSX-pmW2YCvK7akPQuNqbOldG-4wwlWJAFoDbPl3namxtFEQpmTVVjD2XoWLLBDEmnfE2xunVvrVFB3XZ2x_kqcd3Bbmr601qEmJbrBL3YL-Uq3w3q1dZuLel5750E29wkXxiTWlTfsVtB77Q0qcs7r3a8zVfSLgmbTCS38VWvbIhaDG0-TM4aB9zjwlY72plrZ5zz9mIEGl9uGwT--VEIB5jo0B9_OsV6lcbKi1E_DCGe69uOQS22LBdIFwhsIZi0pWd-K8ldn7pFbgfRSBgl6cdZoywKWSRcfVt49Nv9D8aeUHaqa27RvaWEtz7PbGuV_bEP-kBnD8h9F7zQE8vEh6Sji0NydFLIqlxc0TcU5cS4T3NI7kydauOI_GjxlALLaJuntCqp4ymteUqRp7TFU9rwFGdwPKXIU2p5CtPSHU8p8tQMSep4Sg1PqePpI3L-4f3ZeOK5ZiBewrlfeeDJcn-ofRZFUmQR90dDBaGLLwQL4AWGmVnoSDMjJFBMREkQZMLPZCpDzROhFHtMDoqy0E8JBS9XBRm4ZWqQcC3h-lRyMQKeSXgC87uE1VjES1vzJcZYORzE_iAGMOMGzBjBjIeiS46vwdbcClcwHrEueVXjGIMNNxtzstDlZm20lSMGFrNLnlh4m3sdPZ7tPfOc3G3-Oy_IQbXa6JfgJ1fqGFn5CwxTvBM |
link.rule.ids | 315,786,790,27955,27956 |
linkProvider | Geneva Foundation for Medical Education and Research |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Opportunity+for+intervention+to+achieve+American+Heart+Association+guidelines+for+optimal+lipid+levels+in+high-risk+women+in+a+managed+care+setting&rft.jtitle=Circulation+%28New+York%2C+N.Y.%29&rft.au=Mosca%2C+Lori&rft.au=Merz%2C+Noel+Bairey&rft.au=Blumenthal%2C+Roger+S&rft.au=Cziraky%2C+Mark+J&rft.date=2005-02-01&rft.eissn=1524-4539&rft.volume=111&rft.issue=4&rft.spage=488&rft_id=info:doi/10.1161%2F01.CIR.0000153859.66086.85&rft_id=info%3Apmid%2F15687138&rft.externalDocID=15687138 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0009-7322&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0009-7322&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0009-7322&client=summon |